We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00091234
Recruitment Status : Unknown
Verified July 2012 by European Organisation for Research and Treatment of Cancer - EORTC.
Recruitment status was:  Recruiting
First Posted : September 9, 2004
Last Update Posted : July 24, 2012
Sponsor:
Collaborator:
Information provided by (Responsible Party):

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2013
  Study Completion Date : No date given
Publications:
Amadori S, Suciu S, Selleslag D, et al.: Phase II-III study of gemtuzumab ozogamicin monotherapy versus best supportive care in older patients with newly diagnosed AML unfit for intensive chemotherapy: first results of the EORTC-GIMEMA AML-19 trial. [Abstract] Blood 112 (11): A-762, 2008.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):